Severe hemolytic anemia and skin reaction in a patient treated with imatinib.

@article{Arriba2003SevereHA,
  title={Severe hemolytic anemia and skin reaction in a patient treated with imatinib.},
  author={J-J De Arriba and Cristina Ner{\'i}n and Elizeth Garc{\'i}a and Lorenzo G{\'o}mez-Aldarav{\'i} and B. Rodrı́guez Vila},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2003},
  volume={14 6},
  pages={962}
}
Imatinib is an inhibitor of specific protein tyrosine kinases, which was recently approved for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors [1]. Although cutaneous reactions are quite common with this agent [2, 3], anemia in patients receiving therapy for gastrointestinal tumors is rare and has been related to… CONTINUE READING